Olumacostat glasaretil is a potent, selective inhibitor of acetyl-CoA carboxylase (ACC), a key enzyme in de novo fatty acid synthesis. It was investigated for the topical treatment of acne vulgaris. By inhibiting ACC in sebaceous glands, it reduces fatty acid production and sebum levels, a key factor in acne development. This mechanism showed efficacy against both inflammatory and non-inflammatory acne lesions in clinical studies. As a topical agent, it offers targeted action with minimal systemic exposure, limiting side effect risks. Development was discontinued after Phase 2 trials, and it is now available as a research chemical (≥98% purity).